Table 3.
Comparison of previous studies of long-term viral response following interferon-based treatment
| Author, Year | Study Design | Treatment | Number with SVR | Follow-Up (mo)a | Long-Term Response Methodology | Long-Term Response (%) |
|---|---|---|---|---|---|---|
| Studies in nonhemodialysis population | ||||||
| Shindo, 1995 | Single center | IFN | 21 | 6 | Probability | 95 |
| Marcellin, 1997 | Single center | IFN | 75 | 42 (6–85) | Probability | 96 |
| Larghi, 1998 | Single center | IFN | 25 | 33 (15–74) | Probability | 92 |
| Lau, 1998 | Single center | IFN | 5 | NR (72–156) | Probability | 100 |
| Reichard, 1999 | 3 RCT | IFN | 26 | 59 (36–100) | Probability | 92 |
| Scvarcz, 1999 | Single center | IFN + RBV | 12 | 18 | Probability | 92 |
| Bruno, 2001 | 2 RCT | IFN | 36 | 78 | Probability | 100 |
| McHutchison, 2001b | 3 RCT | IFN + RBV (24) | 112 | 42 | Kaplan–Meier | 97 |
| IFN + RBV (48) | 151 | 42 | Kaplan–Meier | 99 | ||
| IFN | 73 | 42 | Probability | 96 | ||
| Veldt, 2004 | Meta-analysisc | IFN | 286 | 59 (12–120) | Kaplan–Meier | 95 |
| Tsuda, 2004 | Single center | IFN | 38 | 82 (53–144) | Probability | 100 |
| Dalgard, 2005 | 1 RCT | IFN +/− RBV | 27 | 59 (7–77) | Probability | 98 |
| Formann, 2006 | Single center | PEG-IFN | 187 | 29 (12–172) | Probability | 100 |
| Camma, 1999 | Meta-analysis | IFN | 453 | NR (18–93) | Pooled probability | 91 |
| Studies in transplant recipients | ||||||
| Bizollon, 2002 | Single center study of liver transplant recipients | IFN + RBV | 14 | 30 | Probability | 93 |
| Current study | ||||||
| Gordon | Hemodialysis | IFN or PEG-IFN | 121 | 18 (1–78) | Probability | 92 |
| Life table analysis | 86 (77–96) | |||||
| Gordon | Hemodialysis with subsequent kidney transplant | IFN or PEG-IFN | 45d | 20 (2–88) | Probability | 93 |
| Life table analysis | 95 (89–100) | |||||
IFN, interferon, NR, not reported; PEG-IFN, pegylated-interferon; RBV, ribavirin; RCT, randomized controlled trial.
Follow-up time reported is median, with range in parentheses, unless otherwise specified. Follow-up times reported are after sustained virologic response for consistency with our analysis. Original studies largely reported follow-up time from end of treatment.
Published as abstract in 2001 American Association for the Study of Liver Diseases meeting.
Meta-analysis of individual patient data from eight randomized controlled trials or prospective studies of interferon.
Thirty two patients had long-term HCV RNA data for both the HD and kidney transplant states. We analyzed these patients in both groups.